NCT07211633Phase 3Active not recruiting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-31Estimated
Enrollment · participants360Estimated
Source updated2026-10-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 31 Dec 2026. After: 31 Oct 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Area under the curve (AUC) from 0 to Week 24 of Ublituximab. After: Measure: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab.

Check registry source